0.45Open0.47Pre Close20 Volume39 Open Interest9.00Strike Price962.00Turnover41.12%IV2.64%PremiumDec 20, 2024Expiry Date0.29Intrinsic Value100Multiplier24DDays to Expiry0.23Extrinsic Value100Contract SizeAmericanOptions Type-0.5941Delta0.4278Gamma16.75Leverage Ratio-0.0069Theta-0.0032Rho-9.95Eff Leverage0.0086Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet